Oculus imaging device approved by FDA
The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.
The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.
The slim, ergonomically-designed device features a 5.7" LCD display, and comprises an autorefractor combined with a Scheimpflug based non-contact pachymeter, to photograph and measure corneal thickness and lens refractive power. It can be set to PARK, ARK or P measurement modes.
The PARK 1 will be launched officially at this year's American Academy of Ophthalmology (AAO) meeting, which is to be held on November 8–11 in Atlanta, GA, US.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
